Kurs
+3,43%
Kurs
+3,43%
Open
16,65
High
17,48
Low
16,31
Close
17,17
Kursutveckling under dagen för detta pressmeddelande
(NOK).
Likviditet
23,7 MNOK
Likviditet
23,7 MNOK
Rel. mcap
2,51%
Antal aktier
1 402 939
Likviditet under dagen för detta pressmeddelande
Kalender
| Tid* | ||
| 2025-02-26 | 06:30 | Bokslutskommuniké 2024 |
| 2024-11-27 | - | Kvartalsrapport 2024-Q3 |
| 2024-08-21 | - | Kvartalsrapport 2024-Q2 |
| 2024-05-21 | - | X-dag ordinarie utdelning NYKD 0.00 NOK |
| 2024-05-16 | - | Årsstämma |
| 2024-05-14 | - | Kvartalsrapport 2024-Q1 |
| 2024-02-28 | - | Bokslutskommuniké 2023 |
| 2023-11-15 | - | Kvartalsrapport 2023-Q3 |
| 2023-08-23 | - | Kvartalsrapport 2023-Q2 |
| 2023-05-16 | - | Kvartalsrapport 2023-Q1 |
| 2023-05-12 | - | X-dag ordinarie utdelning NYKD 0.00 NOK |
| 2023-05-11 | - | Årsstämma |
| 2023-02-28 | - | Bokslutskommuniké 2022 |
| 2022-11-23 | - | Kvartalsrapport 2022-Q3 |
| 2022-08-24 | - | Kvartalsrapport 2022-Q2 |
| 2022-05-16 | - | Kvartalsrapport 2022-Q1 |
| 2022-05-13 | - | X-dag ordinarie utdelning NYKD 0.00 NOK |
| 2022-05-12 | - | Årsstämma |
| 2022-03-31 | - | Bokslutskommuniké 2021 |
| 2021-12-22 | - | Extra Bolagsstämma 2021 |
| 2021-11-17 | - | Kvartalsrapport 2021-Q3 |
| 2021-08-26 | - | Kvartalsrapport 2021-Q2 |
| 2021-05-12 | - | Kvartalsrapport 2021-Q1 |
| 2021-05-06 | - | X-dag ordinarie utdelning NYKD 0.00 NOK |
| 2021-05-05 | - | Årsstämma |
| 2021-04-21 | - | Bokslutskommuniké 2020 |
| 2020-11-17 | - | Kvartalsrapport 2020-Q3 |
| 2020-08-27 | - | Kvartalsrapport 2020-Q2 |
| 2020-07-07 | - | Split NYKD 1:5 |
| 2020-07-06 | - | Extra Bolagsstämma |
| 2020-05-12 | - | Kvartalsrapport 2020-Q1 |
| 2020-04-22 | - | Extra Bolagsstämma |
Beskrivning
| Land | Norge |
|---|---|
| Lista | OB Match |
| Sektor | Hälsovård |
| Industri | Bioteknik |
2023-10-31 14:41:11
Reference is made to the stock exchange announcement published by Nykode
Therapeutics ASA (the "Company") on 25 October 2023 regarding the successful
placing of a private placement of new shares (the "Private Placement") and the
disclosure of shareholding by Datum Opportunity AS and Jan Haudemann-Andersen
resulting from lending of shares in connection with settlement of the Private
Placement.
The borrowed shares have now been re-delivered following registration of the
share capital increase pertaining to the Private Placement. Datum Opportunity AS
holds a total of 26,000,000 shares, equal to 8.00% of the new share capital of
the Company, and Jan Haudemann-Andersen and companies controlled by him
(including Datum Opportunity AS) holds a total of 41,189,050 shares, equal to
12.67% of the new share capital of the Company.
This announcement is made in accordance with Section 4-2 of the Norwegian
Securities Trading Act.